News | January 22, 2015

Post-operative Radiation Therapy Improves Survival for Patients with Resected Non-small Cell Lung Cancer

Analysis of more than 2,100 patients treated from 2004 to 2006 supports addition to chemotherapy

Non-small cell lung cancer, NSCLC, post-operative radiation therapy, PORT

January 22, 2015 — Patients who received post-operative radiation therapy (PORT) lived an average of four months longer when compared to patients who had the same disease site, tumor histology and treatment criteria but did not receive PORT, according to research presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. The symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC) and The University of Chicago Medicine.

This study reviewed the records of non-small cell lung cancer patients treated from 2004 to 2006 from the National Cancer Data Base (NCDB), a joint endeavor of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The study authors acquired the data for patients who had surgically resected non-small lung cancer with pathologically involved N2 (pN2) lymph nodes (tumors had spread to the lymph nodes in the center of the chest) and who received chemotherapy. The database was further queried to exclude patients with positive margins, incomplete survival data, those who did not receive adjuvant chemotherapy, histology other than NSCLC, and patients treated with Cobalt-60, non-beam radiotherapy or neoadjuvant radiotherapy. Two thousand one hundred and fifteen patients (2,115) met all of the study criteria. Forty-three percent of patients (918) received PORT; 56.6 percent of the patients (1,197) were not treated with PORT.

Factors associated with overall survival (OS) were assessed through a multivariable Cox proportional hazards model. Inverse probability of treatment weighting (IPTW) using the propensity score was also implemented to reduce biased treatment selection. Using an adjusted Kaplan-Meier estimator and the weighted log-rank test based on the IPTW, patients treated with PORT had an improved overall survival (median survival time) of 42 months compared to 38 months for the patients not treated with PORT (p=0.048).

Multivariable analysis revealed that female gender, adenocarcinoma histology, higher income, urban/rural setting vs. metropolitan setting, lower T state, 1-2 involved lymph nodes vs. =3 examined and involved lymph nodes, and younger age correlated to better OS (p<0.05). No direct relation was found between the effects of PORT and the number of involved lymph nodes.

“These results reinforce the value of PORT for non-small cell lung cancer patients with involved mediastinal lymph nodes. Our data indicates that with modern radiotherapy equipment and treatment techniques, PORT can improve survival for these patients,” said John L. Mikell, MD, lead study author and chief resident in the Department of Radiation Oncology at Emory University Winship Cancer Institute in Atlanta. “The data in this study, the largest, most recent cohort of patients with involved mediastinal nodes treated with chemotherapy reinforce that PORT should be considered in addition to chemotherapy following resection of non-small cell lung cancer.”

For more information: www.astro.org

Related Content

DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer
News | Lung Cancer | August 02, 2017
To raise public awareness of lung cancer—the leading cancer killer of men and women—the American Lung Association's...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
Overlay Init